Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma

Faith E. Davies(NYU Langone Health), Kenneth C. Anderson(Dana-Farber Cancer Institute), Yu‐Tzu Tai(Harvard University), Suzanne Lentzsch(Columbia University Irving Medical Center), Paul G. Richardson(Harvard University), Noopur Raje(Massachusetts General Hospital), Steven P. Treon(Dana-Farber Cancer Institute), Teru Hideshima(Harvard University), Gareth J. Morgan(Hywel Dda University Health Board), Deepak Gupta(University of Leeds), Gloria Young(University of Leeds), Robert Schlossman(University of Leeds), Boris K. Lin(University of Leeds), George W. Muller(University of Leeds), Dharminder Chauhan(Cancer Clinic), David Stirling(University of Leeds), Klaus Podar(Dana-Farber Cancer Institute)
Blood
July 1, 2001
10.1182/blood.v98.1.210
Cited by 905

Related Papers

Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: Report of the BIOMED-2 Concerted Action BMH4-CT98-3936
|Leukemia|2003|3k
The Global Syndemic of Obesity, Undernutrition, and Climate Change: The Lancet Commission report
|The Lancet|2019|3k
International Staging System for Multiple Myeloma
|Journal of Clinical Oncology|2005|2.9k
A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma
|New England Journal of Medicine|2003|2.6k
International uniform response criteria for multiple myeloma
|Leukemia|2006|2.6k